# Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

> **NCT04297150** · — · UNKNOWN · sponsor: **Fundación de Investigación Biomédica - Hospital Universitario de La Princesa** · enrollment: 700 (estimated)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Edoxaban
- **DRUG:** Rivaroxaban
- **DRUG:** Dabigatran

## Key facts

- **NCT ID:** NCT04297150
- **Lead sponsor:** Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-18
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04297150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04297150, "Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04297150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*